Does Rallies show Form 4 insider transactions for ALXO?

Yes. Rallies tracks ALXO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ALXO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ALXO. It does not provide personalized investment advice.

ALXO (ALX Oncology Holdings Inc. Common Stock) Stock Analysis - Insider Trades

ALX Oncology Holdings Inc. Common Stock (ALXO) is a publicly traded Healthcare sector company. As of May 20, 2026, ALXO trades at $1.96 with a market cap of $269.13M and a P/E ratio of -1.03. ALXO moved +1.79% today. Year to date, ALXO is +77.68%; over the trailing twelve months it is +364.09%. Its 52-week range spans $0.40 to $2.66. Analyst consensus is strong buy with an average price target of $4.75. Rallies surfaces ALXO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ALXO stock inside the company?

Recent ALXO insider activity includes Lettmann Jason sold 12.31K, Pinto Shelly sold 903, Pinto Shelly sold 565, GOODMAN COREY S bought 3.18M, and Pinto Shelly sold 3.92K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ALXO Key Metrics

Key financial metrics for ALXO
Metric	Value
Price	$1.96
Market Cap	$269.13M
P/E Ratio	-1.03
EPS	$-1.90
Dividend Yield	0.00%
52-Week High	$2.66
52-Week Low	$0.40
Volume	416.13K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-101.69M
Gross Margin	0.00%

Recent ALXO Insider Trades

Lettmann Jason sold 12.31K (~$26.71K) on Mar 19, 2026.
Pinto Shelly sold 903 (~$1.96K) on Mar 19, 2026.
Pinto Shelly sold 565 (~$1.28K) on Feb 18, 2026.
GOODMAN COREY S bought 3.18M (~$5.00M) on Feb 2, 2026.
Pinto Shelly sold 3.92K (~$4.36K) on Jan 6, 2026.

Latest ALXO News

ALX Oncology Posts 60% Response Rate in HER2 Trial, Secures $150M — May 8, 2026
Evorpacept Plus Zanidatamab Yields 100% ORR, 22.1-Month PFS in HER2+ mBC — May 7, 2026
ALX Oncology Narrows 2026 Loss Estimate to $0.88, Shares Up 80.5% — Mar 10, 2026
ALX Oncology Secures $150M, Evorpacept Hits 65% ORR, ALX2004 Enters Dose Level Three — Mar 4, 2026
ALX Oncology Posts 56% Response Rate, Extends Runway with $140.4m Financing — Feb 27, 2026

ALXO Analyst Consensus

5 analysts cover ALXO: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.75.

Common questions about ALXO

Who is trading ALXO stock inside the company?: Recent ALXO insider activity includes Lettmann Jason sold 12.31K, Pinto Shelly sold 903, Pinto Shelly sold 565, GOODMAN COREY S bought 3.18M, and Pinto Shelly sold 3.92K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ALXO?: Yes. Rallies tracks ALXO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ALXO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ALXO. It does not provide personalized investment advice.